SANOFI’S MASTERMIND AT WORK (BUY; 27% UPSIDE)
26/01/21 -"Since our last Teaser in November 2019, it has been a roller-coaster ride for Sanofi (Buy, France). While an impressive mid-term growth strategy and robust Q4-19 results were appreciated by the ..."
Pages
75
Language
English
Published on
26/01/21
You may also be interested by these reports :
26/04/24
Hikma’s qualitative Q1 commentary entailed a positive tone for all the segments. Moreover, the management reaffirmed the full-year guidance. Since ...
25/04/24
The Q1 results topped expectations, led by robust performances across all the key segments. While the management maintained its 2024 guidance, an ...
25/04/24
Q1 results surpassed expectations, on the back of a strong showing from immunology drug Dupixent, RSV vaccine Beyfortus and the new launches of ...
24/04/24
The Q1 sales met the street’s expectations, although forex, off-patent drugs’ generic/biosimilar erosion and declining COVID-19 sales adversely ...